Figure 1 | Scientific Reports

Figure 1

From: Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial

Figure 1

Enriched heparin inhibits SARS-CoV-2 infection in Vero cells. (A) Percentage of virus load inhibition in the supernatant of cells infected with SARS-CoV-2 (102 TCID50/mL) cultured with increasing enriched heparin concentration (up to 250 ug/ml) for 72 h. (B) Three different times of heparin addition were evaluated, comprising the virus absorption (AD), post-infection (PI), and adsorption plus post-infection (FT). Data are representative of mean (SEM) of 4 replicates from 2 independent experiments. Data were analysed using Two-Way ANOVA with Dunnett’s multiple comparisons test. *p < 0.05; **p < 0.01.

Back to article page